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Abstract: Approximately 20–30% of patients with metastatic renal cell carcinoma (mRCC) in first-line
treatment with tyrosine kinase inhibitors (TKIs) do not respond due to primary resistance to this drug.
At present, suitable robust biomarkers for prediction of a response are not available. Therefore, the aim
of this study was to evaluate a panel of microRNAs (miRNAs) in nephrectomy specimens for use as
predictive biomarkers for TKI resistance. Archived formalin-fixed, paraffin embedded nephrectomy
samples from 60 mRCC patients treated with first-line TKIs (sunitinib, n = 51; pazopanib, n = 6;
sorafenib, n = 3) were categorized into responders and non-responders. Using the standard Response
Evaluation Criteria in Solid Tumors, patients with progressive disease within 3 months after the start
of treatment with TKI were considered as non-responders and those patients with stable disease and
complete or partial response under the TKI treatment for at least 6 months as responders. Based on a
miRNA microarray expression profile in the two stratified groups of patients, seven differentially
expressed miRNAs were validated using droplet digital reverse-transcription quantitative real-time
polymerase chain reaction (RT-qPCR) assays in the two groups. Receiver operating characteristic
curve analysis and binary logistic regression of response prediction were performed. MiR-9-5p and
miR-489-3p were able to discriminate between the two groups. MiR-9-5p, as the most significant
miRNA, improved the correct prediction of primary resistance against TKIs in comparison to that of
conventional clinicopathological variables. The results of the decision curve analyses, Kaplan-Meier
analyses and Cox regression analyses confirmed the potential of miR-9-5p in the prediction of
response to TKIs and the prediction of progression-free survival after the initiation of TKI treatment.
Keywords: renal cell carcinoma; metastasis; tyrosine kinase inhibitors; sunitinib; primary resistance;
microRNAs; prognostic indicator
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1. Introduction
The introduction of targeted therapy agents has significantly improved the overall survival of
patients with metastatic renal cell carcinoma (mRCC) [1]. The tyrosine kinase inhibitors (TKIs) sunitinib,
pazopanib or sorafenib are frequently used standard-of-care options for the first-line treatment of
these patients [2,3]. The tumor response to these drugs is generally evaluated according to the
standard Response Evaluation Criteria in Solid Tumors (RECIST) based on computed tomographic
or magnetic resonance imaging data of the metastatic lesions [4,5]. A recent large sunitinib global
expanded-access trial with 3353 evaluated mRCC patients reported an objective response rate of
approximately 20% (defined as the sum of complete and partial responses according to RECIST criteria)
and a clinical benefit (sum of objective response plus stable disease≥3 months) of approximately about
76% [6]. Thus, 20–30% of patients are primarily refractory to sunitinib treatment. This phenomenon of
non-responsiveness is termed primary or intrinsic resistance, in contrast to the secondary or acquired
resistance that often develops after 6–15 months of treatment [7]. In both cases, the mechanisms are
obviously multifactorial and have not yet been satisfactorily examined [8,9].
A reliable prediction of primary resistance to TKIs during first-line therapy could be helpful
to avoid unnecessary treatment of patients and to save time in selecting other potentially beneficial
therapeutic options [2]. Since patients with a primary resistance exhibit a poor overall survival [10,11],
they could also be classified by a successful prediction of this resistance into a different prognostic
group according to different clinical score systems before initiation of first-line targeted therapy [12–14].
Current prognostic measures consist of hematologic values, a clinical performance index and the time
interval between first RCC diagnosis and occurrence of metastases (mostly after partial nephrectomy),
but their capability is limited to correctly predicting the response to targeted therapy [15].
Thus, a necessary research task consists of the identification of new molecular markers that could,
alone or in combination with the conventional clinicopathological variables, improve reliable prediction
of therapeutic responses for mRCC patients [15,16]. The expression of several tissue and circulating
analytes has been shown to correlate with the efficacy of sunitinib or other targeted agents in mRCC
patients (reviewed in [9,17,18]). However, so far, there has been no approved biomarker to correctly
predict the response to targeted therapy in these patients [17,19]. In this regard, microRNAs (miRNAs,
miRs) as small, non-protein-coding transcripts could be considered as suitable biomarkers because of
their important role as posttranscriptional regulators in all network processes of carcinogenesis and
metastasis [20]. Several studies that have identified differentially expressed miRNAs in nephrectomy
specimens of RCC patients with subsequent tumor relapse while under TKI therapy have confirmed this
assumption [21–27]. However, different definitions of the clinical endpoints of progression-free survival or
time to progression were used in these studies to classify two groups with different responses to sunitinib
or other TKIs. As clearly stated in a currently published review of the studies carried out so far, this
is, among other reasons, one decisive cause for the partly inconsistent results between the studies [28].
Therefore, we used a more practical outcome scenario. We defined patients as non-responders having
primary resistance if at the first RECIST re-assessment (generally within 3 months) after the start of
treatment with TKI they were found to have progressive disease and we defined patients as responders if
they had complete or partial response and stable disease under TKI for at least 6 months.
Under these conditions, the aims of this study were (a) to identify typical miRNA profiles
in nephrectomy specimens from two groups of mRCC patients under first-line TKI treatment,
(b) to explore the most discriminative miRNAs as predictive biomarkers of primary resistance
to first-line TKI therapy by reverse-transcription quantitative real-time polymerase chain reaction
(RT-qPCR) using the sophisticated droplet digital PCR technique and (c) to validate the predictive
capability using different evaluation approaches such as receiver-operating characteristic curve analysis
(ROC), decision curve analysis and univariate and multivariate analyses in comparison to that for
conventional clinicopathological variables. Collectively, this study was primarily focused on the
possible development of a potential predictive marker of primary resistance in the first-line treatment
of mRCC patients with TKIs.
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2. Materials and Methods
2.1. Patients and Samples
The study was approved by the local Ethics committee of the University Hospital Charité
(EA1/153/07; EA1/134/12) and informed patient consent was obtained. The study was carried
out in accordance with the Declaration of Helsinki. The general criteria of the guidelines “Standards
for Reporting of Diagnostic Accuracy” (STARD) and “Reporting Recommendations for Tumor Marker
Prognostic Studies” (REMARK) were considered [29,30]. The flow diagram shown in Figure 1 outlines
the steps performed in this retrospective study completed in July
Figure 1. Flowchart of the study. Abbreviations: FFPE, formalin-fixed, paraffin-embedded; RCC, renal
cell carcinoma; RT-qPCR, reverse transcription real time quantitative polymerase chain reaction; TKIs,
tyrosine kinase inhibitors.
The study included 60 RCC patients who underwent radical nephrectomy from 2000 through
2011 and were subsequently treated with TKIs as first-line therapy using the standard treatment
schedule after they developed metastasis (Table 1). The patients had not previously received
other therapies. Criteria of the RECIST guidelines were used to characterize the response to this
treatment [4,5]. According to these criteria, after the first restaging assessment that was generally
performed 3 months after the initiation of TKI treatment, patients with progressive disease were
considered as non-responders with primary resistance and those patients with partial response or
stable disease under the TKI treatment for at least 6 months as responders.
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Table 1. Clinicopathological characteristics of the metastatic renal cell carcinoma cohort after radical










Age, median years (95% CI) 62.0 (59.0–67.2) 59.0 (53.6–67.0) 0.427
Tumor characteristics 0.678
clear cell carcinoma 38 17
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Response to targeted therapy
Partial response 11 -
Stable disease 30 -
Progressive disease - 19
Median months survival (95% CI) §
Progression-free 16.2 (11.4–21.0) 2.6 (2.3–3.5) <0.0001
Overall 67.6 (40.1–96.2) 20.9 (13.3–37.4) <0.0001
Abbreviations: CI, confidence interval; FG, histopathological grading according to Fuhrman; M, distant metastasis; pN,
pathological nodal status; pT, pathological tumor classification; R, surgical margin classification; TKI, tyrosine kinase
inhibitors. * p values from Fisher’s exact test, Chi-square test or Mann-Whitney U test indicate the association of the
responder status with the clinicopathologic characteristics in the patients. † Imaging techniques was used to assess the
presence/non-presence of metastases (M1/M0) before surgery. ‡ Unclassified patients. § Data were taken from the
Kaplan-Meier analyses. The median survival corresponds to the time at which the survival probability is 50%.
Tumors were classified according to the 2002 TNM classification and the Fuhrman grading system
by an experienced pathologist (E.K.) [31,32]. Archived FFPE tissue samples that were prepared from the
surgically removed tumors for routine diagnostic purposes were used in this study. Hematoxylin-eosin
stained histological FFPE sections were prepared to identify areas of normal and tumor tissue.
These regions of interest were punch biopsied using 1.5 mm diameter needles. Only tumor samples
with more than 80% cancer cells were considered for further analysis. Non-malignant tissue with
a distance of >20 mm to the cancer tissue was collected from 45 patients of the study cohort for
comparison purposes. These samples were selected to exclude, as far as possible, any alteration of the
non-neoplastic tissue by the tumor [33,34].
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2.2. RNA Extraction, MicroRNA Array Cards and miRNA Quantification
Total RNA was isolated from the dissected FFPE tissue samples (mean ± SD, 15.5 ± 4.6 mg) using
an miRNeasy FFPE Kit (Qiagen, Hilden, Germany; Cat. No. 217504) according to the manufacturer’s
instructions. Briefly, this process included steps for paraffin removal, lysis (TissueLyser, Qiagen;
2 × 1 min, 30 Hz, 5 mm stainless steel beads) with proteinase K digestion at 50 ◦C, on-column
DNase I digestion, binding and washing of total RNA including miRNA on a MinElut spin column
membrane. Total RNA was eluted from the membrane with 16 µL of nuclease-free water and the RNA
concentration and purity were measured on a NanoDrop ND-1000 spectrophotometer (NanoDrop
Technologies, Wilmington, DE, USA). The isolated RNA was stored at −80 ◦C until analysis.
For miRNA signature profiling, the preconfigured TaqMan® Array Human MicroRNA A + B
Cards Set v3.0 (Thermo Fisher Scientific, Waltham, MA, USA; Cat. No. 4444913) was applied according
to the manufacturer’s instructions. Two RNA sample pools consisting of equal RNA aliquots from ten
different samples of the patients of each group were used for multiplexed cDNA synthesis. cDNAs were
measured on a ViiA7 real-time PCR system (Thermo Fisher Scientific) under default thermal-cycling
conditions for the 384-well TaqMan microRNA array cards. Quantification cycles (Cq values) were
generated by SDS software v2.3 and were exported for further calculations. Further details are given
in Supplementary Information S1 and Supplementary Table S1.
For the validation of miRNA profiling results, a two-step procedure was chosen. RT-qPCR
measurements were performed first on a Light-Cycler 480 (Roche, Mannheim, Germany) using TaqMan
miRNA assays (Thermo Fisher Scientific) as previously described [35–38] and here summarized in
Supplementary Information S2 including checklist data (Supplementary Tables S2 and S3) of the MIQE
guidelines “Minimum Information for Publication of Quantitative Real-Time PCR Experiments” [39]
and “Minimum Information for Publication of Quantitative Digital PCR Experiments” [40] with
additional Supplementary Figures S1–S3 and Supplementary Tables S4–S8. Based on the preliminary results,
the validation was performed in a second step analyzing cDNAs with the droplet digital PCR technique
on a droplet QX200 digital PCR instrument (Bio-Rad Laboratories GmbH, Munich, Germany). The same
TaqMan assays as used on the LightCycler were utilized for the droplet digital PCR (Supplementary Table
S4). An aliquot of 20 µL of the PCR mix including 10 µL of 2× PCR Supermix for Probes (No dUTP; Cat.
No. 186-3023), 1 µL of TaqMan MicroRNA Assay primer (Thermo Fisher Scientific; part No. 4427975),
an miRNA-specific cDNA sample (2 µL for miR-9-5p and miR-489-3p, 1 µL of cDNA for miR-223-3p)
and 7.0 or 8.0 µL of nuclease-free water was filled into one sample well and 70 µL of Droplet Generator
Oil for Probes (Cat. No. 186-3005) was filled into the corresponding oil well of a DG8 Cartridge
(Bio-Rad). The cartridges were closed with DG8 gaskets (Cat. No. 186-3009) and placed into the
QX200 droplet generator for the partition of each sample into 20000 droplets. After droplet formation,
40 µL was transferred into a 96-well PCR plate (TwinTec PCR Plate, semi-skirted, Cat. No. 0030128575;
Eppendorf, Germany). The plate was heat sealed (Pierceable Foil Heat Seal, Cat. No. 181-4040,
Bio-Rad) with a PX1 PCR Plate Sealer and then placed into a PCR thermal cycler (T100 Thermal cycler,
Bio-Rad). The PCR run conditions were set as follows: 10 min at 95 ◦C for enzyme activation, followed
by 45 amplification cycles: 94 ◦C denaturation for 30 s and 56 ◦C annealing/extension for 1 min,
a finishing step of enzyme deactivation at 98 ◦C for 10 min and a hold cooling step at 12 ◦C. All ramp
rates were set to 2.5 ◦C/s. After finishing the PCR reaction, the plate was placed into a QX200 Droplet
Reader and the positive/negative droplets were analyzed and counted using QuantaSoft Software
v.1.7 (Bio-Rad Laboratories, Inc., CA, USA). Results are given as copies per µL of the PCR reaction mix.
Further details are summarized in the checklist of the digital MIQE guidelines [40] and Supplementary
Information S2 (Supplementary Figures S3 and S4, Tables S6–S8).
2.3. Data Analysis and Statistics
qBasePLUS, v.3.0 software (Biogazelle, Zwijnaarde, Belgium) was used for the analysis of RT-qPCR
data. Statistical analyses (Mann-Whitney U test, Spearman rank and Pearson correlations as well as
ROC, Kaplan-Meier, binary logistic regression and Cox regression analyses) were performed with SPSS 23
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(SPSS Inc., Chicago, IL, USA) including the bootstrap module, GraphPad Prism 7.04 (GraphPad Software,
La Jolla, CA, USA) and MedCalc 18.5 (MedCalc Statistical Software, Ostend, Belgium). The decision
curve analysis [41] for models with the corresponding indicated markers were constructed as previously
described [42]. A p value less than 0.05 (two-sided) was considered statistically significant. MedCalc was
used for sample size determinations. MiRTarBase (http://miRTarBase.mbc.nctu.edu.tw/) [43], miRWalk2.0
(http://zmf.umm.uni-heidelberg.de/mirwalk2) [44] and DIANA-TarBase v7.0 (http://www.microrna.gr/
tarbase) [45] databases were used to evaluate validated and predicted miRNA-target interactions.
3. Results
3.1. Study Design, Patient and Sample Characteristics
To avoid both type I and type II errors, the conventional thresholds of α = 5% (significance level)
and β = 20% (power of 80%) were selected for sample size calculation on the basis of ROC analysis.
An area under the ROC curve (AUC) of 0.75 was defined as the required discrimination criterion
considering a 2 to 1 ratio of responder to non-responder in the study cohort. Under this condition,
a discriminative capacity could be expected by studying 30 responders and 15 non-responders in
each group. Thus, primary tumor samples from 41 patients with a partial response or stable disease
criteria [4,5], defined as responders and from 19 patients who showed progressive disease after the
initiation of the TKI therapy within a median period of 2.6 months, defined as non-responders, were
included in this retrospective study. The clinicopathological data of the patients are summarized in
Table 1 and did not differ between the two groups except for their metastatic status. Kaplan-Meier
analyses of progression-free survival and overall survival showed a poor clinical outcome with shorter
survival rates in patients with primary resistance (Figure 2).020406080100 (b) Overall survival0 20 40 60 80 100 120 140 160 180Time (months)Overall suvival probability (%) ResponderVNon-responderVLogrank testChi-squared=17.1; 3<0.0001020406080100 (a) Progression-free survival0 10 20 30 40 50 60Time (months)Progression-free survival (%) ResponderVNon-responderVLogrank testChi-squared=84.8; 3<0.0001
Figure 2. Kaplan-Meier curves in mRCC patients under first-line TKI therapy. (a) Progression-free survival.
(b) Overall survival. Patients were classified as non-responders (n = 19) and responders (n = 41) as
shown in Table 1 and explained in the text. The log-rank test was used to confirm significant differences
between the survival probabilities. Abbreviations: mRCC, metastatic renal cell carcinoma; TKI, tyrosine
kinase inhibitors.
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The purity of the isolated RNA samples did not differ between the study groups and fulfilled the
purity criterion for down-stream measurements summarized in Supplementary Information S2.
3.2. Array-based Identification of Deregulated miRNAs
To identify putative miRNAs as predictors of primary resistance to sunitinib, we performed a
miRNA TaqMan Array Card screening analysis on pools of total RNA isolated from 10 randomly
selected patients from the two groups (Figure 1; Supplementary Information S1). For the detection
of differentially expressed miRs, delta Cq values of the corresponding miRNAs were calculated.
From 754 miRNAs on the cards, after elimination of undetermined and very poorly expressed miRNAs
(Cq > 34 in both groups), 309 miRNAs remained for further calculations (Supplementary Table S1).
Using a Cq difference of ≥1.5, 11 increased and 35 decreased miRNAs between non-responders and
responders were identified. We selected 11 miRs (miR-9-5p, miR-20b-5p, miR-203a-3p, miR-204-5p,
miR-223-3p, miR-342-3p, miR-483-5p, miR-489-3p, miR-500a-5p, miR-885-5p and miR-1269a; miRBase
22 release, http://mirbase.org) with good PCR curves on the array cards for further validation.
3.3. Droplet Digital RT-qPCR Validation of Selected miRNAs
To assess in a first validation step whether the assay-based selected miRNAs could also be reliably
measured using individual RT-qPCR assays, we analyzed the RNA pools used in the TaqMan Array
Card screening analysis on the LightCycler. MiR-342-3p and miR-1269a of the 11 abovementioned
miRNAs were detected at Cq values > 34 or showing a Cq difference < 1.0 between the pools of the
two groups. Because we consider these analytical conditions as not suitable for a fit-for-purpose
assay, we disregarded them in the further validation process. The Cq values of the remaining nine
miRNAs obtained on the TaqMan arrays and measured on the LightCycler were strongly correlated
(Supplementary Figure S2). These data confirmed the feasibility of measuring these miRNAs using
TaqMan assays on either the real-time LightCycler or the droplet QX200 digital instrument.
To take advantage of the high analytical performance of the droplet digital PCR procedure,
we continued the measurements utilizing this technique. However, the assays for miR-20b-5p and
miR-483-5p did not form proper droplet cluster pictures making reasonable measurements impossible.
Thus, we continued the droplet digital PCR measurements with the other seven miRNAs (miR-9-5p,
miR-203a-3p, miR-204-5p, miR-223-3p, miR-489-3p, miR-500a-5p, and miR-885-5p). The expression
data from the patients classified as responder and non-responder patients (Table 1) are shown in
Figure 3.
The level of miR-9-5p was significantly increased, whereas the level of miR-489-3p was decreased,
in non-responder patients compared to that in responder patients. This differential expression
effect was accentuated when the ratio of miR-9-5p to miR-489-3p was established. However, it was
additionally remarkable that both miRNAs were not differentially expressed between non-malignant
adjacent and malignant tissue samples (Supplementary Figure S4). This feature distinctly contrasted
with the other examined miRNAs without the differential expression in the responder-dependent
groups since their expression was either increased (miR-885-5p and miR-223-3p) or decreased
(miR-203a-3p, miR-204-5p and miR-500a-5p) in tumor samples in comparison to non-malignant
adjacent tissue samples (Supplementary Figure S4).
The clinicopathological variables pT stage, Fuhrman grade and metastatic status did not correlate
with the expression of the seven miRNAs (P values between 0.162 and 0.952) except for the Fuhrman
grade with miR-9-5p (rs = 0.324, p = 0.013) and miR-223-3p (rs = −0.311, p = 0.017) (Supplementary
Table S9). Significantly different correlation coefficients of the miRNA expression in dependence
on the clinicopathological variables were not observed (p < 0.05) between the responder and
non-responder patients.














































































































(h) Ratio of miR-9-5p to miR-489-3p
p<0.0001
Figure 3. miRNA expression data in nephrectomized tumor samples of mRCC patients with different
responses to first-line TKI therapy. Using droplet digital RT-PCR, the selected seven miRNAs after
pretesting validation by RT-qPCR (see Figure 1 and text in Section 3.3) were measured as shown in
the subfigures (a–g) in primary tumor samples of metastatic RCC patients who were responders (R+,
n = 41) or non-responders (R−, n = 19) to TKI treatment. Furthermore, the ratio of the two significant
miRNAs, miR-9-5p to miR-489-3p, was shown in subfigure (h). Medians with interquartile ranges are
given, and significant differences between the study groups were calculated by Mann-Whitney U test.
Abbreviations: mRCC, metastatic renal cell carcinoma; TKIs, tyrosine kinase inhibitors.
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3.4. miRNAs as Predictors of Primary Resistance to the TKI Treatment and Clinical Outcome
ROC analysis was used to characterize the discriminative potential of the single and combined
miRNAs as well as their combination with clinicopathological variables to response/non-response to
TKI treatment (Table 2, Figure 4). As expected from the expression data shown in Figure 2, the single
miRNAs miR-9-5p and miR-489-3p showed statistically significant AUCs. Including all miRNAs in a
model built by binary logistic regression analysis or the combination of miR-9-5p and miR-489-3p in
different way, a comparable discrimination between the two groups was achieved in comparison with
miR-9-5p (Table 2). For practical reasons, we continued our model calculations with miR-9-5p.
Table 2. Receiver-operating characteristic curve analyses of miRNAs in nephrectomized tumor tissue
samples to discriminate between patients as responders and non-responders to the treatment with
tyrosine kinase inhibitors.




Differentiating Ability at the
Youden Index * Overall Correct
Classification (%)
Sensitivity (%) Specificity (%)
Single miRNAs
miR-9-5p 0.83 (0.71–0.91) <0.0001 74 88 73
miR-203a-3p 0.53 (0.40–0.66) 0.718 63 51 68
miR-204-5p 0.51 (0.38–0.65) 0.861 89 29 68
miR-223-3p 0.52 (0.03–0.65) 0.871 53 61 68
miR-489-3p 0.69 (0.58–0.80) 0.014 79 59 68
miR-500a-5p 0.52 (0.38–0.65) 0.846 16 73 68
miR-885-5p 0.57 (0.44–0.70) 0.353 58 63 72
Combined miRNAs
All miRNAs † 0.79 (0.66–0.88) <0.0001 95 59 77
miR-9/miR-489 0.83 (0.73–0.93) <0.0001 69 87 73
miR-9 + miR-489 † 0.82 (0.71–1.00) <0.0001 97 21 72
Abbreviations: AUC, area under the receiver-operating characteristics curve; CI, confidence interval. * The cutoff at
the maximum value of the Youden index corresponding to the overall diagnostic effectiveness with the equal weight
to false positive and false negative values was used for this assessment. † Calculated by full binary logistic regression.
Figure 4 shows the ROC curves and the decision analyses of the combined clinicopathological
variables in Model 1, with miR-9-5p as the best single discriminative miRNA in Model 2 and the
combination of the clinicopathological variables with miR-9-5p in Model 3. MiR-9-5p revealed a higher
AUC value than that of clinicopathological variables of Model 1 and improved the discrimination
ability in combination with the clinical variables (Figure 4a). In the respective decision curve
analysis (Figure 4b), this net benefit of miR-9-5p was also displayed compared to that of the use
of clinicopathological variables as predictors of primary resistance to the TKI treatment.
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Figure 4. ROC curve analysis (a) and decision curve analysis (b) showing the benefit of miR-9-5p for
predicting primary resistance to TKIs in mRCC patients in comparison to that for clinicopathological
variables. Binary logistic regression models were calculated. Model 1 included the clinicopathological
variables age, sex, tumor stage, Fuhrman grade, metastatic and resection status as indicated in
Table 1; Model 2 considered only continuous miR-9-5p values; and Model 3 was a combination of the
clinicopathological variables and miR-9-5p values (Model 1 + Model 2). Output data of binary logistic
regression models were used for ROC and decision curve analyses as previously described [41,42].
The areas under the ROC curves (and the 95% confidence intervals) were 0.72 (0.59–0.83) for Model 1,
0.83 (0.71–0.91) for Model 2, and 0.89 (0.78–0.91) for Model 3. Abbreviations: ROC, receiver-operating
characteristic; mRCC, metastatic renal cell carcinoma; TKIs, tyrosine kinase inhibitors.
It was furthermore of interest whether miR-9-5p in these three prediction models for the primary
resistance could also be used as a predictive marker for progression-free and overall survivals.
Comparison of the Kaplan-Meier curves of progression-free survival according to the conventional
clinicopathological variables and miR-9-5p supports this view (Figure 5a–c). These analyses
demonstrate that the combination of conventional clinicopathological parameter data with the most
significant miR-9-5p could improve the reliability of forecasting primary resistance to TKIs. In the
multivariate Cox regression model of progression-free survival with all clinicopathological variables,
miR-9-5p showed a hazard ratio of 3.23 (95% CI 1.67 to 6.28; p = 0.0005) and remained as the
only significant factor after a backward elimination process. For the prediction of overall survival,
the inclusion of miR-9-5p in the model with the clinicopathological variables showed merely a rather
adjunctive role (Figure 5d–f).
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Fig re 5. Kaplan-Meier curves of progression-free survival and overall survival based on the prediction
models of primary resistance to the treatment with TKIs. The variables of the prediction models
were used in the binary logistic regression analyses. Model 1 included the clinicopathological
variables age, sex, tumor stage, Fuhrman grade, metastatic and resection status as indicated in
Table 1; Model 2 considered only continuous miR-9-5p values; and Model 3 was a combination
of the clinicopathological and miR-9-5p values. The propensity scores of logistic regression analyses as
outputs of the predicted probabilities were used to calculate the best discriminatory cutoffs using the
Youden index in ROC analysis. Based on these cutoffs indicated in the respective figures, the output
data were dichotomized and the corresponding Kaplan-Meier curves for progression-free survival
(left column, subfigures (a–c)) and overall survival (right column, subfigures (d–f)) were generated.
TKI, tyrosine kinase inhibitors.
Using the miRTarBase, miRWalk2.0 and DIANA-TarBase v.7.0 databases with regard to experimentally
validated miRNA-gene interactions [43–45], 310 target genes for miR-9-5p (Supplementary Table S10)
and one target for miR-489 (PTPN11, protein tyrosine phosphatase, non-receptor type 11) have been
documented so far.
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4. Discussion
This study identified the expression of increased miR-9-5p and decreased miR-489-3p in
nephrectomy specimens of RCC patients as predictive biomarkers of primary resistance to the first-line
treatment with tyrosine kinase inhibitors. As the combination of both miRNAs did not improve the
predictive ability of miR-9-5p, we focused on data evaluation of miR-9-5p for practical purposes.
The identification of novel biomarkers that could be informative for therapeutic efficacy, safety
and tolerability of targeted drugs is of general interest and, at the same time, a great challenge [19].
Despite the development and wide use of targeted therapies for mRCC, no molecular marker is
currently applied in practice for these predictive purposes in the management of mRCC patients [17].
This lack of markers applies not only to tissue markers but also to circulating markers from blood or
plasma/serum [46,47], as currently summarized in two overviews [9,17].
Our results confirm other study data regarding miRNAs as helpful tools for this current issue in
the application of TKIs in the first-line treatment of mRCC patients [21–27,48]. However, the different
results between those studies and our data should be mentioned. Three studies exclusively examined
ccRCC samples [21–23], and another as well as our study included approximately 10% papillary
RCC [24]. Similar to our approach, five working groups used a two-stage design to identify potential
predictive miRNAs in nephrectomy specimens. Such an approach consisted of an initial array- or
sequencing-based screening step to discover deregulated miRNAs associated with a therapeutic
response to a TKI in either fresh-frozen RCC or FFPE RCC samples followed by a second RT-qPCR
validation step for selected miRNAs [21–25]. Moreover, Gamez-Pozo et al. [48] examined miRNAs
in peripheral blood samples from mRCC patients as predictors of resistance to sunitinib. All of
these studies revealed significant relationships between miRNAs and progression-free survival as an
indicator of the response to sunitinib, similar our study cohort treated with sunitinib and the two other
guideline-approved TKIs, pazopanib and sorafenib. However, different miRNAs were recommended
by all of the studies as best predictors of resistance to sunitinib. Kovacova et al. [27] confirmed this less
than satisfactory situation. The authors aimed to validate miRNAs identified in previous studies as
predictive markers of response to sunitinib therapy, but only two out of 10 examined miRNAs were
shown to be discriminative between responders and non-responders in their study cohort.
Preanalytical and analytical variations might be one reason for the different results observed
between the studies. However, the selected time interval after the initiation of TKI-based therapy
for evaluating the response and, in consequence, stratification of the patients into corresponding
cohorts, likely had much more influence on the expression differences [28]. Our approach was clearly
focused on primary resistance [8,9] to identify miRNA expression characteristics in nephrectomy
specimens, which could be indicative in predicting therapeutic efficacy for the respective patient.
This approach could be a basis for a companion diagnostic test performed before therapy is initiated
to prove whether the patient could benefit from this treatment or not [49]. Therefore, we defined
patients with progressive disease in the first restaging visit after the start of targeted therapy (median:
2.6 months) and compared their expression data with patients who suffered progressive disease much
later (median: 16.2 months). This approach corresponds to the stratification concept applied in the
studies by Berkers et al. [21] and Prior et al. [22], who also used similar extreme endpoints (2.7 vs.
24.2 and 2–3 vs. 31–32 months). Other studies stratified the patients being treated with sunitinib into
cohorts according to an endpoint of progressive-free survival for 9 or 12 months under sunitinib [23,24].
By using those time criteria, it cannot be excluded that the non-responder group defined in such a
way could also include patients with a secondary resistance, which is often observed 6 months after
initiation of sunitinib treatment [7].
Based on the 46 differentially expressed miRNAs in our array-based screening process, we decided
to use droplet digital RT-PCR as favorable analytical method for further quantification of the seven
selected miRNAs. The droplet digital RT-PCR technique enables quantification of the absolute
number of transcripts and therefore circumvents a potentially erroneous normalization procedure [25].
Although the model with all seven miRNAs achieved a perfect discrimination between the two cohorts
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(Table 2), we did not use this model to avoid the risk of overfitting bias. Our study intention was
to improve the basic predictive ability of clinicopathological data by combining them with the best
quantitative biomarkers according to the principle of “do not use more laboratory tests than absolutely
necessary” [50]. The use of a single marker, miR-9-5p, the ratio of miR-9-5p to miR-489-3p and their
combination with clinicopathological variables in binary logistic regression models resulted in a similar
high discrimination capacity and confirmed our strategy (Table 2, Figure 4a). Thus, a focus on the best
discriminative miRNA miR-9-5p was feasible and justified. This result is also clearly shown in the
decision curve analysis complementing the ROC curves (Figure 4a,b). Decision-curve analysis is a
helpful decision-making tool when different markers should be compared with regard to their clinical
value [41]. The increased net benefit of miR-9-5p alone and in combination with the clinicopathological
variables becomes obvious over a wide range of threshold probabilities in comparison to the model
with the clinicopathological variables alone (Figure 4b).
The missing correlations of miRNAs with the clinicopathological risk factors pT stage, Fuhrman grade
and metastatic status, especially those of the two differentially expressed miR-9-5p and miR-489-3p in
responders and non-responders, are remarkable. This uncorrelated differential expression of miRNAs in
relation to these known disease variables is a striking hallmark of potential orthogonal biomarkers [51].
This particularity of orthogonal markers must be regarded as a precondition that these markers are
independent factors in a prognostic model. These independent variables in a multivariable model adjusted
by clinicopathological factors are frequently associated with the subsequent discovery of novel downstream
targets and pathways [51]. Our study proved that miR-9-5p remained such an independent variable
in multivariable Cox regression models (Figure 5). This kind of marker could improve recently used
prognostic models to guide the treatment choices of patients [12–14].
The identified differentially expressed miRNAs in TKI-non-responsive patients are not only
useful as predictive biomarkers. Since miRNAs have fundamental regulatory functions in various
signal cascades and metabolic pathways, it can be assumed that they can be helpful for a deeper
understanding of the underlying mechanisms involved in primary resistance to TKIs. MiR-9-5p is the
major transcript from the three genes MIR9-1, MIR9-2 and MIR9-3 that are located on chromosomes 1, 5 and
15. Increased expression of miR-9 was found in liver carcinoma [52,53], breast cancer [54] and esophageal
carcinoma [55], while decreased expression was described in colorectal carcinoma [56], gastric and
ovarian cancer [57,58]. These different expression characteristics imply that the miRNA has cancer-specific
functional roles. A few reports exist about the expression of miR-9-5p in ccRCCs [59–61]. Specific expression
data of miR-9 in RCC tissue and cancer cell lines have been reported in relation to methylation status
with divergent results [59,61]. Thus, the significance of this miRNA with regard to the sunitinib resistance
as observed in our expression data can only be deduced from the functional data explored in other
tumor entities. Experimentally validated interactions of miR-9 with 310 genes (Supplementary Table S10)
have been documented so far in the miRTarBase, miRWalk2.0 and DIANA-TarBase databases [43–45].
Several of these genes are involved in cancer-related pathways such as VEGF, angiogenesis, apoptosis
and E-cadherin, as shown in the KEGG pathway database (http://www.kegg.jp/). For example,
in breast cancer and esophageal carcinoma, miR-9 has been found to promote epithelial-mesenchymal
transition as an important mechanism in tumor progression [54,55,62]. In addition, it is of interest
regarding the new therapy concept of immune checkpoint blockade using antibodies against PD-1 that
miR-9 is involved, together with its target gene PRDM1 (PR domain containing 1, with ZNF domain)
and cytokine IL-2, in T-cell dysfunction [63,64]. For miR-489, only one validated interaction with
PTPN11 was documented in the three databases. Increased expression of PTPN11 is currently
postulated to be a key element in intrinsic and acquired resistance to other targeted cancer drugs [65].
However, the relationships to TKI therapy in mRCC patients have not yet been examined.
Limitations of this study must be mentioned. The genetic heterogeneity of RCCs is a general
inherent limitation of this tissue-based study [66]. This heterogeneity between the primary RCC and
its metastatic lesions is also a further reason for the expression differences observed between different
studies as well as between screening and validation cohorts within the same study [22,24]. To overcome
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this difficulty of heterogeneity, the examination of multiple samples or several mixed samples from the
same tumor has been suggested [23,67]. The more specific limitations of our study are its retrospective
design and the lack of external validation of the data. Under the aspect of the selected strict rules to
assemble two different patient cohorts under TKI treatment, the retrospective design for this pilot study
should be considered acceptable. In this regard, all analyses were therefore performed in a blinded
manner before the data were statistically evaluated. To exclude type I and II errors as far as possible,
we followed a sample size calculation with a high effect size as explained. Moreover, the additional
digital PCR analyses and the approach of internal validation of data by bootstrapping in addition to
the decision curve analyses as shown in our previous studies of biomarkers [33,50] support the validity
of our study. A real limitation of our study is the lack of functional experiments to show the potential
effects of miR-9-5p and miR-489-3p in association with primary resistance. However, investigation of
the functional role of these miRNAs was beyond the scope of this study as we pointed out the aims
of this study in the Introduction. In addition, the functional role of a biomarker may be helpful to
explain its biological rationale, but is not pivotal for its application in clinical practice to prove its
clinical benefit in comparison to the currently used decision-making procedures [68].
5. Conclusions
In conclusion, miRNA expression patterns in nephrectomy specimens might be helpful in
predicting primary resistance to first-line TKI treatment in mRCC patients. In this study, miR-9-5p
alone and in combination with conventional clinicopathological factors could improve the objectivity
of the decisions of clinicians and patients in individualized patient counseling in determining whether
the patient would benefit from the drug or would fail to respond to the drug. In addition, the inclusion
of predictive biomarkers into prognostic models could improve the accuracy and robustness of those
models. Considering the findings and critical points discussed in this article, all of these results make
further prospective studies worthwhile. This should also include experimental work regarding the
possible functional role of miRNAs in primary resistance to first-line TKI treatment in mRCC patients.
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